🇺🇸 FDA
Patent

US 12077785

Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 12077785 (Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof) held by SOTIO BIOTECH INC. expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SOTIO BIOTECH INC.
Grant date
Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/53, A61K2239/55